Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Clinical & Translational Immunology|February 25, 2021
Human neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variantCheryl Yi-Pin Lee, Siti Naqiah Amrun, Rhonda Sin-Ling Chee, et al.
Scientific Reports|November 7, 2023
Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta waveYun Shan Goh, Siew-Wai Fong, Matthew Zirui Tay, et al.
Journal of Clinical Immunology|October 30, 2021
Robust Virus-Specific Adaptive Immunity in COVID-19 Patients with SARS-CoV-2 Δ382 Variant InfectionSiew-Wai Fong, Nicholas Kim-Wah Yeo, Yi-Hao Chan, et al.
EMBO Molecular Medicine|May 7, 2021
Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2Yi-Hao Chan, Siew-Wai Fong, Chek-Meng Poh, et al.
Frontiers in Immunology|December 1, 2022
Waning of specific antibodies against Delta and Omicron variants five months after a third dose of BNT162b2 SARS-CoV-2 vaccine in elderly individualsYun Shan Goh, Angeline Rouers, Siew-Wai Fong, et al.
Frontiers in Immunology|July 19, 2023
Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBBZi Wei Chang, Yun Shan Goh, Angeline Rouers, et al.
The Journal of Infectious Diseases|November 23, 2023
Variant-Specific IgA Protects Against Omicron InfectionYun Shan Goh, Siew-Wai Fong, Pei Xiang Hor, et al.
Lancet (London, England)|August 22, 2020
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort studyBarnaby E Young, Siew-Wai Fong, Yi-Hao Chan, et al.
Vaccine|September 6, 2024
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trialXuan Ying Poh, Anthony Torres-Ruesta, Terence Yoong, et al.
Ebiomedicine|August 13, 2024
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trialXuan Ying Poh, I Russel Lee, Chee Wah Tan, et al.
Pageof 15